accessibility menu, dialog, popup

UserName
Viewing profile as user:

Imidazopyridines

Organic heterocyclic compounds that contain an imidazole ring fused to a pyridine ring. Imidazole is five-membered ring with three carbon atoms and two nitrogen atoms; pyridine is a six-membered ring with five carbon atoms and one nitrogen atom.

Filtered Search Results

Products from some of our suppliers do not display in filtered search results. Please clear all filters to see these products.

Narrow Results

Narrow Results

category

brands

  • (4)

special interests

  • (4)
Search Within Results
Keyword Search:
1 – 4 of 4 results
1

Medchemexpress LLC DGAT1-IN-3 | 939375-07-2 | 99.9% | 420.39 | 50 MG
SDP

DGAT1-IN-3 is a potent, selective and orally bioavailable inhibitor of DGAT-1, with IC50s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. It could be used to research of obesity, dyslipidemia, and metabolic syndrome.

  • IC50 of 38 nM for human DGAT-1; 120 nM for rat DGAT-1
  • Inhibits human DGAT1 expressed in CHOK1 cells with an EC50 of 0.66 μM
  • Blocks the human ether-a-go-go-related gene (hERG) encoded potassium channel with an IC20 of 0.2 μM
  • Reduces weight gain and plasma triglycerides, and improves lipid profile (5-50 mg/kg; p.o once daily for three weeks)
  • Exhibits good oral bioavailability (77%) and a maximum exposure level in plasma (Cmax) of 24 μM (50 mg/kg; p.o)
  • Exhibits terminal elimination half-lives (1.95 h) and low clearance (13.5 mL/min/kg) (5 mg/kg; i.v)

ENCOMPASS_PREFERRED
2

Medchemexpress LLC 4-Oxazolecarboxamide, N-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-2-phenyl-5-(trifluorom | 939375-07-2 | 99.9% | 420.39 | 100 MG
SDP

DGAT1-IN-3 is a potent, selective, and orally bioavailable inhibitor of DGAT-1. It can be used for research on obesity, dyslipidemia, and metabolic syndrome.

  • Potent, selective, and orally bioavailable inhibitor of DGAT-1.
  • Inhibits human DGAT-1 with an IC50 of 38 nM.
  • Inhibits rat DGAT-1 with an IC50 of 120 nM.
  • Supports research into obesity.
  • Supports research into dyslipidemia.
  • Supports research into metabolic syndrome.
  • Reduces cumulative body weight gain in DIO rats.
  • Reduces weight gain and plasma triglycerides.
  • Improves lipid profiles.

ENCOMPASS_PREFERRED
3

Medchemexpress LLC 4-Oxazolecarboxamide, N-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-2-phenyl-5-(trifluoromethyl)- | 939375-07-2 | 99.9% | 420.39 | 5 MG
SDP

DGAT1-IN-3 is a potent, selective, and orally bioavailable inhibitor of DGAT-1, with IC50s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. It can be used for research on obesity, dyslipidemia, and metabolic syndrome.

  • Potent, selective, and orally bioavailable inhibitor of DGAT-1.
  • IC50s: 38 nM (human DGAT-1); 120 nM (rat DGAT-1).
  • Reduces weight gain and plasma triglycerides, and improves lipid profile in animal models.
  • Exhibits good oral bioavailability (77%) and a maximum exposure level in plasma (Cmax) of 24 μM (50 mg/kg; p.o).
  • Exhibits terminal elimination half-lives (1.95 h) and low clearance (13.5 mL/min/kg) (5 mg/kg; i.v).
  • Appearance: solid, light yellow to yellow color.

ENCOMPASS_PREFERRED
4

Medchemexpress LLC 4-oxazolecarboxamide, N-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-2-phenyl-5-(trifluoromethyl)- | 939375-07-2 | 99.9% | 420.39 g/mol | C20H19F3N4O3 | 10 MG
SDP

DGAT1-IN-3 is a potent, selective, and orally bioavailable small-molecule inhibitor of diacylglycerol O-acyltransferase 1 (DGAT-1) intended as a research reagent for studies of lipid metabolism, obesity, and related metabolic disorders.

  • Potent DGAT-1 inhibition with human IC50 38 nM and rat IC50 120 nM.
  • High purity as verified by LCMS (99.92%).
  • Molecular formula C20H19F3N4O3 and molecular weight 420.39 g/mol.
  • Suitable for in vitro and in vivo pharmacology studies of lipid metabolism.
  • Available in small research quantities (1 mg, 5 mg, 10 mg).
  • Structural formula and quality documentation provided in the product datasheet and COA.

ENCOMPASS_PREFERRED